
Sahajanand Medical Technologies Limited IPO
What the filing actually says
Our read of the offer document and the exchange data — not the issuer's summary of itself
Dates
The issuer's tentative timetable — a date passing is not confirmation the step completed
- Opens15 Oct 2026
- Closes19 Oct 2026
- Allotment21 Oct 2026
- Listing23 Oct 2026
Grey market premium
Unofficial dealer quotes — not published by NSE, BSE, SEBI or the company
What this number is not. Grey-market premium is an unregulated, thinly-traded quote from private dealers. It is not a forecast of the listing price, it is not verifiable, and it can be moved by the same people who benefit from it looking high. We publish it because you will look it up anyway — and we deliberately do not convert it into an expected listing gain, because that arithmetic implies a reliability the number has never earned. For what actually happened to comparable issues, see recent outcomes below.
The offering
Terms, structure and who is selling
What happened to comparable issues
The last 8 issues to list with a recorded opening price, most comparable first
Past issues are context, not a forecast — this issue is a different company at a different price. We show it because "how have issues like this one actually opened" is a question with a real answer, and grey-market premium is not that answer.
About Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies Limited develops, manufactures, and sells medical devices used in vascular and structural heart interventions. Founded in 2001, the company offers vascular intervention products, including coronary stents and coronary balloon catheters, and structural heart products, including transcatheter aortic valve implantation (TAVI) devices and occluders. Its portfolio also includes renal stents, peripheral drug-coated balloons, and traded medical products. The company markets its products through direct sales, hybrid, and distributor-led models. In FY26, it generated revenue from 77 countries, including India, with operations across Europe and other international markets. It currently operates three manufacturing facilities, two in India and one in Thailand. Additionally, it has two research and development centres, located in India and Thailand, focused on medical device development and product improvements. Use of proceeds: The IPO is an offer-for-sale (OFS). The company will not receive any proceeds from the offer. Net proceeds from the offer will go to the promoter selling shareholders in proportion to the number of shares offered by them for sale. The primary objective of the offer is to achieve the benefits of listing the equity shares on the stock exchanges, which is expected to enhance the company’s visibility and brand recognition. Listing will also provide liquidity to the existing shareholders and create a public market for the company’s shares in India.
Offer documents
The primary sources everything above is drawn from
Common questions
What is the Sahajanand Medical Technologies Limited IPO GMP today?
The most recent grey-market premium recorded for Sahajanand Medical Technologies Limited is ₹40 per share — about 11.6% over the ₹344 upper band. Grey-market premium is an unofficial, unregulated quote from private dealers. It is not published by NSE, BSE, SEBI or the company, and it is not a forecast of the listing price.
What is the minimum investment in the Sahajanand Medical Technologies Limited IPO?
One lot is 43 shares, so a retail application at the ₹344 cut-off price blocks ₹14,792. Retail applications are capped at ₹2,00,000; above that you bid in the HNI category, where allotment is proportionate rather than by lottery.
When is the Sahajanand Medical Technologies Limited IPO allotment date?
Allotment is scheduled for 2026-10-21, with listing on 2026-10-23. These dates are the issuer's tentative timetable — a date passing is not confirmation that the step completed. Allotment status is published by the registrar, MUFG Intime India Pvt Ltd.
Disclaimer. Figures are compiled from the issuer's offer document and exchange-published bidding data. Subscription changes until the issue closes, and the final basis of allotment is published by the registrar. Grey-market premium is unofficial and is not a forecast. Nothing here is investment advice or a recommendation — read the offer document and consult a SEBI-registered adviser before applying.

